Abbott (NYSE:ABT) said today that it has been selected by the Japanese Red Cross Society (JRC) to partner in screening the country’s blood donations.
The eight-year contract is for the exclusive supply of serological instrumentation, tests, and consumables used for blood and plasma screening. The JRC screens approximately 5 million blood donations each year, helping ensure a safe supply of products needed for blood transfusions and plasma therapies. Abbott products are used to screen more than 60% of the world’s blood and plasma supply, according to a company statement.
Get the full story on our sister site, Medical Design & Outsourcing.
